These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 32701251

  • 1. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Zhang N, Sun P, Jin H, Yang Y, Zhao Q, Zhou L, Guo L, Yang X, Lu L.
    Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
    [Abstract] [Full Text] [Related]

  • 2. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y, Zhang XL, Liu ZX, Zhao JJ, Pan QZ, Wen XZ, Xiao W, Xu BS, Hong DC, Guo TH, Shen LJ, Fan WJ, Chen HY, Weng DS, Xu HR, Zhou PH, Zhang YZ, Niu XH, Zhang X.
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [Abstract] [Full Text] [Related]

  • 3. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
    Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue XP, Nie LP, Wan J, Lu XP, Zhang W, Ning ZQ.
    Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L, Qiu S, Liu Y, Liu Z, Zheng Y, Su X, Chen B, Chen H.
    Neoplasma; 2016 May; 63(2):193-200. PubMed ID: 26774139
    [Abstract] [Full Text] [Related]

  • 6. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B, He T.
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [Abstract] [Full Text] [Related]

  • 7. Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis.
    Peng J, Li SJ, Fu X, Liu Y, Zhao XL.
    Kaohsiung J Med Sci; 2020 Dec; 36(12):1004-1013. PubMed ID: 32783381
    [Abstract] [Full Text] [Related]

  • 8. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
    Zhang H, Chi F, Qin K, Mu X, Wang L, Yang B, Wang Y, Bai M, Li Z, Su L, Yu B.
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
    [Abstract] [Full Text] [Related]

  • 9. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
    Kong YL, Pan BH, Liang JH, Zhu HY, Wang L, Xia Y, Wu JZ, Fan L, Li JY, Xu W.
    Aging (Albany NY); 2020 Aug 27; 12(16):16083-16098. PubMed ID: 32855355
    [Abstract] [Full Text] [Related]

  • 10. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
    Gao S, Li X, Zang J, Xu W, Zhang Y.
    Anticancer Agents Med Chem; 2017 Aug 27; 17(6):802-812. PubMed ID: 27592546
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
    Yang S, Nan P, Li C, Lin F, Li H, Wang T, Zhou C, Zhang X, Meng X, Qian H, Wang H, Dong M.
    Biomed Pharmacother; 2018 Mar 27; 99():608-614. PubMed ID: 29710459
    [Abstract] [Full Text] [Related]

  • 12. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
    Wu YF, Ou CC, Chien PJ, Chang HY, Ko JL, Wang BY.
    Phytomedicine; 2019 Mar 15; 56():94-102. PubMed ID: 30668358
    [Abstract] [Full Text] [Related]

  • 13. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
    Wang H, Liu YC, Zhu CY, Yan F, Wang MZ, Chen XS, Wang XK, Pang BX, Li YH, Liu DH, Gao CJ, Liu SJ, Dou LP.
    J Exp Clin Cancer Res; 2020 Dec 09; 39(1):278. PubMed ID: 33298132
    [Abstract] [Full Text] [Related]

  • 14. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H.
    Biomed Pharmacother; 2020 Sep 09; 129():110390. PubMed ID: 32563150
    [Abstract] [Full Text] [Related]

  • 15. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
    Guan XW, Wang HQ, Ban WW, Chang Z, Chen HZ, Jia L, Liu FT.
    Cell Death Dis; 2020 Jan 06; 11(1):20. PubMed ID: 31907371
    [Abstract] [Full Text] [Related]

  • 16. The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV-infected patients on suppressive antiretroviral therapy.
    Li JH, Ma J, Kang W, Wang CF, Bai F, Zhao K, Yao N, Liu Q, Dang BL, Wang BW, Wei QQ, Kang WZ, Sun YT.
    HIV Med; 2020 Dec 06; 21(11):747-757. PubMed ID: 33369029
    [Abstract] [Full Text] [Related]

  • 17. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, Zhao W, Zhang H, Sun X, Yang H, Zhang X, Jin J, Jin Z, Li Z, Qiu L, Dong M, Huang X, Luo Y, Wang X, Wang X, Wu J, Xu J, Yi P, Zhou J, He H, Liu L, Shen J, Tang X, Wang J, Yang J, Zeng Q, Zhang Z, Cai Z, Chen X, Ding K, Hou M, Huang H, Li X, Liang R, Liu Q, Song Y, Su H, Gao Y, Liu L, Luo J, Su L, Sun Z, Tan H, Wang H, Wang J, Wang S, Zhang H, Zhang X, Zhou D, Bai O, Wu G, Zhang L, Zhang Y.
    J Hematol Oncol; 2017 Mar 15; 10(1):69. PubMed ID: 28298231
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.